 |
| Josh Passman |
Lansons Intermarket has named Josh Passman, who exited Prosek Partners in 2019 after a more than 12-year run, CEO of the New York financial firm that is part of UK-based Lansons.
He succeeds the leadership team & Intermarket co-founders Matt Zachowski, LI CEO, and Martin Mosbacher, president. They will continue at the firm as senior consultants.
Passman joins LI from PJ Solomon, boutique investment firm, where he was head of marketing & communications.
He told O'Dwyer's that he will better align the brand, culture and capabilities of the firms on both sides of the ocean, while serving as chief liaison between New York and London.
Passman said one way to bridge the culture between the firms is to rotate employees between London and New York, once the COVID-19 crisis has passed.
The new CEO is eager to beef up LI's service capabilities (e.g., social media, digital, content development); tap into Lanson's reputation management offerings, such as its ESG practice; and expand the senior management ranks.
LI will rebrand as Lansons by the end of the year and the firms will have a unified website. A single financial/accounting system will be in place by the end of summer.
The British firm acquired a majority stake in Intermarket in 2019. LI ranks as O'Dwyer's No. 20 financial firm with 2020 fees of $2.5M.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
